Measurable Residual Disease Validated as Strong Predictor of Survival in AML Patients
核心洞察
A pooled analysis of 1,858 AML (搜索) patients from seven randomized trials demonstrated that measurable residual disease (MRD) is a robust individual-level predictor of overall survival, with MRD-positive patients showing twice the risk of death compared to MRD-negative patients.
The study represents the largest dataset of MRD in AML (搜索) to date and showed strong correlation between MRD responses and overall survival (R² = 0.91), particularly among non-transplanted patients (R² = 0.99).
These findings support MRD as a potential surrogate endpoint for accelerated drug approval in AML (搜索), which could enable identification of effective therapies 4-5 years earlier than traditional overall survival endpoints.
A landmark pooled analysis of nearly 2,000 acute myeloid leukemia (搜索) (AML (搜索)) patients has validated measurable residual disease (MRD) as a robust predictor of survival outcomes, potentially paving the way for accelerated drug approvals in this challenging malignancy. The findings, presented at the 2025 American Society of Hematology (搜索) Annual Meeting, represent the largest dataset of MRD in AML patients to date.
The study analyzed data from 1,858 adult AML (搜索) patients across seven randomized phase II/III trials, demonstrating that MRD positivity remains an independent predictor of worse outcomes regardless of assessment method, age, genetics, or treatment arm. Patients with MRD-positive status showed twice the risk of death compared to those achieving MRD negativity (P < 0.0001).
"The individual-level association is pretty striking—[MRD] positivity remains an independent predictor of worse outcomes," said Jesse Tettero, MD, PhD, who led the research while at Amsterdam University Medical Center (搜索) and is now at Virginia Tech FBRI Cancer Research Center (搜索). "It provides stronger prognostic information than any single genetic or molecular marker we currently use."
Strong Individual-Level Surrogacy Demonstrated
By multivariate analysis, MRD was associated with significantly worse overall survival outcomes across all collected studies (HR = 1.66; 95% CI = 1.33–2.07; P < 0.001). The global odds ratio for the association between MRD status and overall survival was 0.39 (95% CI = 0.32–0.47), with consistent results across different patient subgroups.
The analysis included patients from multiple European cooperative group trials: AMLSG 09-09; AML (搜索)-102, AML-103, and AML-132 HOVON-SAKK studies; SAL cohort; and UK-NCRI AML17 trials. All patients had undergone MRD assessment after two chemotherapy cycles using either multiparameter flow cytometry or quantitative polymerase chain reaction for mutant NPM1 (搜索).
Trial-Level Surrogacy Shows Promise with Caveats
For trial-level surrogacy analysis, limited to multiparameter flow cytometry-based MRD assessment (n = 1,268), the overall correlation coefficient (R²) between treatment effect on MRD and overall survival was 0.91 (95% CI = 0.56–1.00). While this demonstrates strong surrogacy, the lower bound of the confidence interval fell below the FDA's predefined threshold of 0.6.
"The lower bound of the confidence interval was 0.56. The FDA requires the lower bound to be above 0.60, so there is some caution to be noted when interpreting these data," Tettero noted during the presentation.
However, among non-transplanted patients, the correlation was even stronger (R² = 0.99; 95% CI = 0.94–1.00), representing what Tettero described as rare agreement for oncologic endpoints. In contrast, transplanted patients showed weaker correlation (R² = 0.54; 95% CI = 0.00–1.00), suggesting transplant status may impact the MRD-survival association at the trial level.
Implications for Drug Development
The findings could significantly accelerate AML (搜索) drug development timelines. "We could identify effective therapies [with MRD] earlier than OS; that could be a benefit of 4 to 5 years. It therefore enables potential accelerated approval…only if the FDA truly regards MRD as a surrogate end point," Tettero explained.
The FDA has already accepted MRD as a surrogate endpoint for multiple myeloma (搜索) but not yet for AML (搜索) due to disease heterogeneity, assessment variability, and lack of trial-level validation. This study addresses those concerns by providing harmonized data across multiple trials using standardized assessment methods.
Study Limitations and Future Directions
The analysis was limited to trials assessing intensive therapy in European settings, with less intensive regimens like venetoclax plus hypomethylating agents (搜索) not represented. Additionally, MRD assays were not fully standardized across clinical trials, potentially contributing to data heterogeneity.
"The quality of [MRD] testing really depends on where and how it's done. Centralized, experienced laboratories deliver accurate and reproducible results, which are essential if [MRD] is to be used for clinical or regulatory decisions," Tettero emphasized.
Future research plans include expanding analyses to account for modern, non-intensive treatment backbones and achieving global harmonization of MRD testing across different treatment modalities. The investigators also aim to promote international data sharing to expand the number of eligible trials for analysis.